This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boston Scientific Launches OptiCross™ Coronary Imaging Catheter In U.S., Europe And Japan

NATICK, Mass., July 24, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its OptiCross™ Coronary Imaging Catheter and has launched the device in the U.S. and Europe.  A launch in Japan is planned for later this month.  OptiCross, a next generation intravascular ultrasound (IVUS) catheter, offers better deliverability and higher resolution imaging to facilitate complex coronary procedures. 

Designed to be compatible with the Boston Scientific iLab® Ultrasound Imaging System, the OptiCross catheter was created with the input of physicians from around the world to reduce the inherent challenges surrounding catheter delivery in complex cases.  The upgraded, low profile delivery system features 5 French guide catheter compatibility, a shorter, tapered tip, a bi-segmented catheter shaft and a redesigned catheter hub for ease of connection. 

"The OptiCross catheter was designed for optimal deliverability and its performance proves it," said Matthew Price, M.D., interventional cardiologist and director of the Cardiac Catheterization Laboratory, Scripps Green Hospital, San Diego.  "Now I can use IVUS technology in complex cases where I would not have been able to deliver an IVUS catheter before." 

Interventional cardiologists use IVUS to see inside coronary arteries and to gain additional information in order to optimize treatment decisions. 

"The OptiCross catheter widens the applicability of ultrasound with the ability to assess disease pre-procedure, without concern regarding ischemia and lesion trauma," said Dr. Neal Uren, clinical director for cardiac services at the Edinburgh Heart Centre, Royal Infirmary, Edinburgh. "The incremental increase in deliverability widens the use of IVUS into more difficult lesion subsets, while maintaining superior image quality."

The benefits of IVUS-guided percutaneous coronary intervention (PCI) were reinforced at TCT 2012 and at EuroPCR in May with the presentation of the ADAPT-DES IVUS sub-study outcomes.  The results showed that IVUS can help improve patient outcomes and change the way physicians approach their cases. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs